During Shanghai Visit PhRMA Chairman Calls For Regulatory Systems To Support Innovation
This article was originally published in The Pink Sheet Daily
Executive Summary
During a three-day visit in Shanghai, PhRMA Chairman Robert Hugin met local stakeholders and outlined the organization’s advocacy priorities in China amidst the evolving Drug Administration Law.
You may also be interested in...
NIH And 10 Biopharmas Hatch Plan To Accelerate And Improve Therapeutic Pathway Research
With $230 million from industry and NIH, the Accelerating Medicines Partnership seeks to hasten and improve the success rate for discovery of biomarkers and therapeutic pathways in Alzheimer’s, type 2 diabetes, rheumatoid arthritis and lupus.
Sanofi-Aventis Asia Pacific R&D Head Frank Jiang Sees Progress And Promise In Research Alliances Across China
BEIJING - As the Paris-headquartered Sanofi-Aventis expands its matrix of research alliances across China, this virtual R&D web is beginning to churn out tangible signs of progress and promise, according to a high-ranking Sanofi scientist based in China
CROs at risk from China's new inventor regulation?
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.